The inefficacy of antiangiogenic therapies

Journal of Angiogenesis Research

Volumn 2, Issue 1, 2010, Pages

  Ribatti, Domenico ^a  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; BORTEZOMIB; CETUXIMAB; DASATINIB; ENDOSTAR; ENDOSTATIN; ERLOTINIB; FLUOROURACIL; IRINOTECAN; LAPATINIB; PANITUMUMAB; PEGAPTANIB; PROTEIN TYROSINE KINASE; RAF PROTEIN; RANIBIZUMAB; SORAFENIB; SUNITINIB; TAXANE DERIVATIVE; THALIDOMIDE; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANTIANGIOGENIC THERAPY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL (TOPIC); DRUG MEGADOSE; GASTROINTESTINAL STROMAL TUMOR; HEAD AND NECK CANCER; HUMAN; HYPERTENSION; KIDNEY CANCER; KIDNEY CARCINOMA; LUNG CANCER; MULTIPLE MYELOMA; NOTE; ONCOGENE C KIT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEINURIA; TUMOR GROWTH;

EID: 78651076751     PISSN: None     EISSN: 20402384     Source Type: Journal    
DOI: 10.1186/2040-2384-2-27     Document Type: Note

References (25)

1. Tumor angiogenesis: therapeutic implications. J Folkman, N Engl J Med 1971 285 21 1182 1186 10.1056/NEJM197111182852108 4938153
2. A system approach to cancer therapy (antiangiogenesis plus standard cytotoxics mechanism(s) of interactions. BA Teicher, Cancer Metastasis Rev 1996 15 2 247 272 10.1007/BF00437479 8842498
3. Bevacizumab plus irinotecan, fluorouracil, and leucovirin for metastatic colorectal cancer. H Hurwitz L Fehrenbacher W Novotny T Cartwright J Hainsworth W Heim J Berlin A Baron S Griffing E Holmgren N Ferrara G Fyfe B Rogers R Ross F Kabbinavar, N Engl J Med 2004 350 23 2335 2342 10.1056/NEJMoa032691 15175435
4. Sorafenib: recent update on activity as a single agent in combination with interferon-alpha 2 in patients with advanced-stage renal cell carcinoma. GK Reddy RM Bukowski, Clin Genitour Cancer 2006 4 4 246 348 10.3816/CGC.2006.n.002
5. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomized controlled trial. GD Demetri AT van Oosterom CR Garrett ME Blackstein MH Shah J Verweij G McArthur IR Judson MC Heinrich JA Morgan J Desai CD Fletcher S George CL Bello X Huang CM Baum PG Casali, Lancet 2006 368 9554 1329 1338 10.1016/S0140-6736(06)69446-4 17046465
6. Molecular targeting therapy for renal cell carcinoma. M Eto S Naito, Int J Clin Oncol 2006 11 3 209 213 10.1007/s10147-006-0577-2 16850127
7. Pathways mediating resistance to vascular endothelial growth factor targeted therapy. LM Ellis DJ Hicklin, Clin Cancer Res 2008 14 20 6371 6375 10.1158/1078-0432.CCR-07-5287 18927275
8. Role of microenvironment in tumor growth and in refractoriness/resistance to antiangiogenic therapies. F Shojaei N Ferrara, Drug Resist Update 2008 11 6 219 230 10.1016/j.drup.2008.09.001
9. E2100: a phase III trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast cancer. KD Miller, Clin Breast Cancer 2003 3 6 421 422 10.3816/CBC.2003.n.007 12636887
10. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. JC Yang L Haworth RM Sherry P Hwu DJ Schwartzentruber SL Topalian SM Steinberg HX Chen SA Rosenberg, N Engl J Med 2003 349 5 427 434 10.1056/NEJMoa021491 12890841
11. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. K Miller M Wang J Gralow M Dickler M Cobleigh EA Perez T Shenkier D Cella NE Davidson, N Engl J Med 2007 357 26 2666 2676 10.1056/NEJMoa072113 18160686
12. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU) leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. F Kabbinavar HI Hurwitz L Fehrenbacher NJ Meropol WF Novotny G Lieberman S Griffing E Bergsland, J Clin Oncol 2003 21 1 60 65 10.1200/JCO.2003.10.066 12506171
13. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. RK Jain DG Duda JW Clark JS Loeffler, Nat Clin Pract Oncol 2006 3 1 24 40 10.1038/ncponc0403 16407877
14. Modes of resistance on antiangiogenic therapy. G Bergers D Hanahan, Nat Rev Cancer 2008 8 8 592 603 10.1038/nrc2442 18650835
15. Biomarkers of response to angiogenesis inhibitors: an open and unsolved question. D Ribatti, Eur J Cancer 2010 46 1 6 8 10.1016/j.ejca.2009.10.022 19926474
16. Tumor-associated endothelial cells with cytogenic abnormalities. K Hida Y Hida DN Amin AF Flint D Panigrahy CC Morton M Klagsbrun, Cancer Res 2004 64 22 8249 8255 10.1158/0008-5472.CAN-04-1567 15548691
17. A new perspective on tumor endothelial cells: unexpected chromosome and centrosome anormalities. K Hida M Klagsbrun, Cancer Res 2005 65 7 2507 2510 10.1158/0008-5472.CAN-05-0002 15805239
18. Antiangiogenic therapy accelerates tumor metastasis. D Ribatti, Leuk Res 2010 20727589
19. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. M Paez-Ribes A Allen J Hudock T Takeda H Okuyama F Vinals M Inoue G Bergers O Casanovas, Cancer Cell 2009 15 3 222 231 10.1016/j.ccr.2009.01.027
20. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. JM Ebos CR Lee W Cruz-Munoz GA Bjarnason JG Christensen RS Kerbel, Cancer Cell 2009 15 3 232 239 10.1016/j.ccr.2009.01.021 19249681
21. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BriTE). A Grothey MM Sugrue DM Purdie W Dong D Sargent E Hedrick M Kozloff, J Clin Oncol 2008 26 5706 5326 5344 10.1200/JCO.2008.16.3212 18854571
22. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. RK Jain, Science 2005 307 5706 58 62 10.1126/science.1104819 15637262
23. Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization. A Claes P Wesseling J Jeuken C Maass A Heerschap WP Leenders, Mol Cancer Ther 2008 7 1 71 78 10.1158/1535-7163.MCT-07-0552 18187807
24. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. O Casanovas DJ Hicklin G Bergers D Hanahan, Cancer Cell 2005 8 4 299 309 10.1016/j.ccr.2005.09.005 16226705
25. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factors, tumor growth factor -1, platelet-derived growth factor, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. M Relf S LeJeune PA Scott S Fox K Smith R Leek A Moghaddam R Whitehouse R Bicknell AL Harris, Cancer Res 1997 57 5 963 969 9041202